Freund et al., 1987 - Google Patents
The effect of different intravenous nutritional regimens on renal function during acute renal failure in the ratFreund et al., 1987
- Document ID
- 10552136170994194573
- Author
- Freund H
- Muggia‐Sullam M
- Lafrance R
- Holroyde J
- Edwards L
- Fischer J
- Publication year
- Publication venue
- Journal of Parenteral and Enteral Nutrition
External Links
Snippet
Acute renal failure in the surgical patient is accompanied by a state of hypermetabolism and increased catabolism. Nutritional therapy is therefore directed at the preservation of body cell mass and protein synthesis for repair of wounds and damaged renal tubuli and for …
- 206010038436 Renal failure acute 0 title abstract description 25
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
- A61K47/16—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Quaternary ammonium compounds, e.g. amides, ureas
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barbul | Arginine: biochemistry, physiology, and therapeutic implications | |
| Savarese et al. | Prevention of chemotherapy and radiation toxicity with glutamine | |
| SCHELTINGA et al. | Glutamine-enriched intravenous feedings attenuate extracellular fluid expansion after a standard stress | |
| EP0318446B1 (en) | Amino acid composition for parenteral nutritional support | |
| US6031000A (en) | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use | |
| AU710527B2 (en) | Amino acid compositions and use thereof in clinical nutrition | |
| GB2029220A (en) | Amino acid solutions for patients with cancers | |
| IL167389A (en) | Leucine-enriched nutritional compositions | |
| HUE032486T2 (en) | Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
| US4438144A (en) | Amino acid preparation and therapy for treatment of stress and injury | |
| US5397803A (en) | Use of glutamine to reduce rate of pathogenic microorganism infection | |
| Boelens et al. | Plasma taurine concentrations increase after enteral glutamine supplementation in trauma patients and stressed rats | |
| FI111127B (en) | Process for preparing a beverage for preoperative use | |
| NZ539579A (en) | Amino acid composition for improving central nervous function | |
| CA1290692C (en) | Substrate composition for treating atherosclerosis | |
| Freund et al. | The effect of different intravenous nutritional regimens on renal function during acute renal failure in the rat | |
| Giordano et al. | Effects of catabolic stress in acute and chronic renal failure | |
| US20080242727A1 (en) | Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass | |
| JP5498491B2 (en) | Nutritional composition and method of using the nutritional composition | |
| EP2106791A1 (en) | Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation | |
| Hwang et al. | The importance of a source of sufficient protein in postoperative hypocaloric partial parenteral nutrition support | |
| JP3914585B2 (en) | Macrophage nitric oxide production enhancer | |
| AU4098993A (en) | Use of alpha-ketoglutarate | |
| US5763485A (en) | Method of treating catabolic, gut-associated pathological processes and impaired host defenses | |
| EP0057209A1 (en) | Novel amino acid preparation and therapy for treatment of stress and injury |